Mirum Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 81 to 91 Tuesday.
IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
History reveals that the best stocks often have an 80 or higher RS Rating at the beginning of a new climb.
Looking For The Best Stocks To Buy And Watch? Start Here
The IBD 50 stock is building a cup without handle with a 35.56 buy point. See if the stock can break out in heavy trading.
Mirum Pharmaceuticals posted 0% earnings growth last quarter, while sales growth came in at 119%.
The company holds the No. 23 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Sarepta Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
